AbbVie
AbbVie and Genmab sign drug development and commercialisation deal worth up to $4bn
June 11, 2020Research and Development AbbVie, Genmab, partnership, pharma
AbbVie has joined forces with Genmab to develop and commercialise three of the latter’s early-stage Genmab drug products – epcoritamab …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
March 18, 2020Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, merger, pharma
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles on the road to regulatory …
Venclyxto combo scores European approval for previously untreated chronic lymphocytic leukaemia
March 13, 2020Medical Communications, Sales and Marketing AbbVie, European Commission, Roche, Venclyxto, pharma
The European Commission has moved to authorise AbbVie and Roche’s B-cell lymphoma-2 (BCL-2) inhibitor Venclyxto (venetoclax) when used in combination …
AbbVie’s Rinvoq hits target in psoriatic arthritis sub-population at Phase 3
February 6, 2020Research and Development AbbVie, Rinvoq, pharma, psoriatic arthritis
AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of …
AbbVie’s Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia
February 3, 2020Sales and Marketing AbbVie, CHMP, EMA, Venclyxto, pharma
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has awarded recommendation to AbbVie’s Venclyxto (venetoclax), …
AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance
January 16, 2020Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis
AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …
AbbVie granted EU marketing authorisation for new arthritis drug
December 19, 2019Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis
AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …
Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia
December 9, 2019Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax
AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition
November 4, 2019Sales and Marketing AbbVie, Humira, pharma
With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …
AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population
October 31, 2019Research and Development AbbVie, Rinvoq, pharma
AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …
Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis
September 27, 2019Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis
Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …
AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients
September 27, 2019Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma
The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …
Ayala hires AbbVie’s Gary Gordon as new CMO
September 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Ayala
AbbVie’s former Vice President of Oncology has moved to Ayala Pharmaceuticals to work as its new Chief Medical Officer (CMO). …
AbbVie shuts down Rova-T development in first-line advanced small-cell lung cancer following another trial failure
August 30, 2019Medical Communications, Research and Development AbbVie, pharma, rova-t, small-cell lung cancer
AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …
Latest content
FibroFind appoints Lee Borthwick as CEO
